Biodexa Pharmaceuticals PLC (BDRX) Share Price

$BDRX: wow....... whatta fizzler.......... couldn't hold on

This market getting MAGA'd biggggggggggggggg time.

Stable GENIUS destroying America piece by piece.... all the trailer parkers fell for the scheme.

Hence the reason for loving the POORLY Educated !


GO $BDRX

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
March 10, 2025

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Clears the way to finalize Phase 3 protocol and recruit sites for U.S.

Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 million Company match

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the results of its Type C meeting with the U.S. Food and Drug Administration (“FDA”) regarding the protocol for the planned registrational Phase 3 study of eRapa in familial adenomatous polyposis (“FAP”).

The Type C meeting followed a productive End of Phase 2 meeting with FDA and the publication of Phase 2 data of eRapa in FAP at six months at Digestive Disease Week in May 2024 and 12 months data at InSight, Barcelona in June 2024. The Type C meeting included a discussion of the statistical plan, the safety database and, most importantly, a composite endpoint for the Phase 3 study. FDA representatives from both Gastroenterology and Oncology Divisions provided valuable input into the proposed program and the Company believes there is a clear path forward for initiation of the registrational Phase 3 study in FAP in the U.S. next quarter.

The planned registrational Phase 3 study of eRapa in FAP will be a double-blind placebo-controlled trial in 168 patients, randomized 2:1 drug / placebo. It is expected the study will be conducted in approximately 30 clinical sites across the US and Europe. The US component of the study will be conducted by LumaBridge, based in San Antonio, Texas and the European component will be conducted by Precision for Medicine LLC. The Phase 3 study is supported by a $17.0 million grant from the Cancer Prevention Research Institute of Texas (“CPRIT”) and a Company match of $8.5 million which has already been paid, in full, into escrow.

Commenting, Dr Gary Shangold, Chief Medical Officer of Biodexa, said, “With no approved products for FAP, we were pleased to collaborate with FDA and our US CRO, LumaBridge, to define the regulatory pathway for eRapa in FAP. Agreement on the composite endpoint, in particular, clears the path to finalize the protocol, recruit the U.S. sites and begin patient enrolment”

$BDRX: 4.75............ she got the fire here





I like what I seeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee

Hit $9 back on Feb. 10............ retest on watch now

GO $BDRX

$BDRX: SPIikkkkkeeeeeeeeeeeee......... now $4

Thar she blowsssssssssssssssssssssssss

Nice pop here in the PM............ up almost a $1


GO $BDRX

not in yet, just watching still.

might be time to buy the dip, still watching

tons of buys out of the gate with a….

…

low volume dip, means most are holding. curious to see what happens next.

acts like it may bounce?

nice run here on good news.

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
February 10, 2025

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum

Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that the US Food and Drug Administration (“FDA”) has granted Fast Track designation for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP). Fast track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

The designation was requested based on the potential for eRapa to address an unmet medical need for FAP, a condition which left untreated universally leads to colorectal cancer. Today, the only treatment option is surgical resection of the colon and/or rectum. Data from the Phase 2 study of eRapa in FAP showed eRapa to be safe and well-tolerated with a median 17% reduction in total polyp burden at 12 months compared with baseline and an overall 75% non-progression rate. Patients in cohort 2 experienced an 89% non-progression rate and 29% median reduction in polyp burden at 12 months compared with baseline. The dosing given to cohort 2 – daily every other week -- is the preferred dosage regimen for the upcoming registrational Phase 3 study.

eRapa in FAP
FAP is characterized as a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option for treating FAP patients, for whom active surveillance and surgical resection of the colon and/or rectum remain the standard of care. If untreated, FAP universally leads to cancer of the colon and/or rectum. There is a significant hereditary component to FAP with a reported prevalence of one in 5,000 to 10,000 in the US1 and one in 11,300 to 37,600 in Europe2. Biodexa has received US FDA Orphan Drug designation for eRapa in FAP and plans to seek a

BDRX: Decent news for Colon/Rectal Cancer issues --- many genetic. (Appears to have tiny stock FLOAT.)

$6.34 +!5% Another 500k floater bottomed at $3s a few weeks ago at $6 was at $15 October with promising pipeline 

BDRX.......................https://stockcharts.com/h-sc/ui?s=BDRX&p=W&b=5&g=0&id=p86431144783

Running again. Wonder where this will stop.

It may never stop!!

BDRX...........................https://stockcharts.com/h-sc/ui?s=BDRX&p=W&b=5&g=0&id=p86431144783

Oink oink

BDRX: Indeed, yesterday was "better"!!! (Today is BONKERS everywhere one looks!!!)

October 15, 2024

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Pharmaceuticals PLC. (the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that a Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for an extension of time to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq Stock Market LLC (“Nasdaq”) set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). As a condition of the Panel’s decision, the Company is required to demonstrate compliance with the Minimum Bid Price Requirement by evidencing a closing bid price of at least $1.00 per share for a minimum of 20 consecutive trading days by October 31, 2024.

BDRX $15s now get ready to do the flip on most

$BDRX $13s pushing $14 hold for the 500knfloater ride

BDRX $12.30 + 140% now we talking better then $11

$6-$9 range this morning $11 yesterday was better so far

BDRX: I think I should rest for awhile, in my "LazyGuy" lounge chair.

Worth a 150% pop?

Biodexa Announces Successful Appeal of Nasdaq Delisting

Pump it $$$$$ 11.03 now

I've been reading up on it.

I'm going to wait to see what happens with the IPO before I jump in. Usually, after the mandatory 30-day quiet period, companies will release positive news to bolster the IPO. Tough to time it right with biotechs. I will probably do nothing right away. Watch LGHL.

Enjoy!

You think BDRX will run again?

Recent news was positive.

Sorry to hear about your loss.

I'm thinking of getting in here now, as it is near its low and I really like their biz. Pick up some LGHL and/or LGHLW. Going to run very soon. Naz business that has 8M OS, 45M in revenue and increasing, and the pps is .20. Waiting on some news near-term.

Don5 blink

Lost a lot of cash here. Took my loss and called it a day now. Watch it run now lol

Dead money here I guess! Unless they find a way to keep from getting down listed

I killed myseld on this one.

They goin to have to do smtg if they want to stay on NASDAQ

Yeah I saw. Needs news or it will go to hell. I hope it dosent cuz I am screwed !!!

BDRX new 52 week low

Yeah I saw . I am so red in here ! It’s super low float but omg the short interest is high. Looking for the next run to a buck to get out and hopefully make few$$. Got stuck on the halt few weeks ago

BDRX new 52 week low

I feel alone over here! We need an update here !!

This one hurts

Will this ever go back up!!!

Men I wish I woke up early! Still stuck in this pos

Biodexa Announces Health Canada Has Approved Phase 2a Dose Confirmation Study Of Tolimidone In Type 1 Diabetes
Benzinga 2024-07-16T08:31:00-04:00

$1 close after 63M volume on 10m float

NOTHING NEFARIOUS GOING ON HERE

BDRX: Bummer.

We sure did but at least we are not 100% this one looks like it has made this move multiple times. So we should be good in the long term. No need to take a huge loss . Just average down when appropriate

BDRX: If you did NOT 'toss-the-farm' at this, well, YES ya might see what transpires in the Post-M here. It appears to be attempting somewhat of a (feeble) 'comeback' the last several minutes. Myself, I simply believe that the RECTUM-stuff this Firm deals with just did NOT resonate well with Wall Street. So, pun intended, WE got it up the ASS!!!!

Maybe after hours?

BDRX: I lost big here, Bro!!! (But during the past 2-weeks, any stock that had ANYTHING to do with CANCER, soared to Mars!!! But, of course, NOT this one!!!)

Same here .